SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC
Position in ARWR — Arrowhead Pharmaceuticals, Inc.
CIK 1638555
Boston, MA
Position in ARWR
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$67,673,432
+$33,806,404 QoQ
Shares Held
830,247
+53.7% QoQ
Ownership
0.588%
of shares outstanding
% of Portfolio
1.76%
of 13F equity value
Holder Rank
#32
of 497 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 80%
Shared 0%
None 20%
Common Shares in ARWR Over Time
Shares Held
Position Value (USD)
Derivatives in ARWR
reported options exposure · as of Mar 31, 2026CallValue
$9,405,000
CallShares
150,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC holds $293,644,011 across 5 Biotechnology names. ARWR ranks #1 (23.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARWR |
Arrowhead Pharmaceuticals, Inc.
This page
|
830,247 | $67,673,432 | |
| 2 | ORKA |
Oruka Therapeutics, Inc.
|
658,301 | $62,650,506 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
787,263 | $62,422,083 | |
| 4 | ABVX |
Abivax S.A.
|
410,000 | $54,636,600 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
621,125 | $46,261,390 |
All Filings in ARWR
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $67,673,432 | 830,247 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $33,867,028 | 540,144 | Shares | Sole | 2026-05-15 | |
| 2026-03-31 | $9,405,000 | 150,000 | Call | Sole | 2026-05-15 | |
| 2025-12-31 | $31,203,300 | 470,000 | Shares | Sole | 2026-02-17 | |
| 2025-12-31 | $13,278,000 | 200,000 | Call | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||